Oramed Pharmaceuticals Inc.
ORMPNasdaqCIK 1176309HealthcareFiscal year ends Dec 31
Reports and events: 334 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-06-1017:28 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-24-051355 |
| 2024-05-1318:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-24-041847 |
| 2024-05-0917:00 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001213900-24-041364 |
| 2024-05-0609:00 ET | 8-K | 8.01 Other events | 0001213900-24-039909 |
| 2024-03-2221:30 ET | SC 13D | Ownership report, active investor | 0001213900-24-025263 |
| 2024-03-1908:00 ET | 8-K | 8.01 Other events | 0001213900-24-023721 |
| 2024-03-1817:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-24-023584 |
| 2024-03-1817:05 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001213900-24-023571 |
| 2024-03-0617:00 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001213900-24-020485 |
| 2024-02-2008:42 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-015108 |
| 2024-01-2316:45 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-24-005780 |
| 2024-01-1916:45 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-24-004905 |
| 2023-12-2109:26 ET | 8-K | 8.01 Other events | 0001213900-23-097505 |
| 2023-12-1816:45 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-23-096536 |
| 2023-11-0917:10 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001213900-23-085310 |
| 2023-09-2616:34 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-23-079586 |
| 2023-09-1308:47 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-23-076238 |
| 2023-08-2218:06 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-23-069538 |
| 2023-08-1017:00 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001213900-23-065678 |
| 2023-08-0908:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-23-064786 |
| 2023-08-0709:20 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-23-063876 |
| 2023-07-1317:00 ET | 8-K | 5.07 Shareholder vote results | 0001213900-23-056806 |
| 2023-05-3117:20 ET | DEF 14A | Proxy statementPeriod 2023-07-13 | 0001213900-23-044530 |
| 2023-05-1117:01 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001213900-23-038593 |
| 2023-05-0116:51 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-23-034728 |
| 2023-03-0617:01 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001213900-23-017837 |
| 2023-02-2717:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001213900-23-014884 |
| 2023-01-1220:00 ET | 8-K | 8.01 Other events | 0001213900-23-002343 |
| 2022-12-1207:39 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-22-078902 |
| 2022-11-1407:55 ET | 8-K | 8.01 Other events | 0001213900-22-071607 |
| 2022-11-1016:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-22-071230 |
| 2022-11-1016:30 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0001213900-22-071222 |
| 2022-09-1917:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001213900-22-057036 |
| 2022-09-1308:52 ET | 8-K | 8.01 Other events | 0001213900-22-055429 |
| 2022-09-0817:06 ET | 8-K | 8.01 Other events | 0001213900-22-054868 |
| 2022-08-1016:45 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0001213900-22-046399 |
| 2022-07-0708:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-22-037750 |
| 2022-06-3016:15 ET | 8-K | 5.07 Shareholder vote results | 0001213900-22-036294 |
| 2022-06-0216:30 ET | DEF 14A | Proxy statementPeriod 2022-06-30 | 0001213900-22-030956 |
| 2022-05-1217:04 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0001213900-22-026004 |
| 2022-04-0408:25 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-22-017667 |
| 2022-02-2817:00 ET | 8-K | 5.03 Amendment to articles or bylaws | 0001213900-22-009794 |
| 2022-01-1209:41 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-22-001660 |
| 2022-01-1116:45 ET | 10-Q | Quarterly reportPeriod 2021-11-30 | 0001213900-22-001563 |
| 2021-12-0808:00 ET | 8-K | 8.01 Other events | 0001213900-21-064085 |
| 2021-12-0717:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-21-063984 |
| 2021-11-2417:15 ET | 10-K | Annual reportPeriod 2021-08-31 | 0001213900-21-062009 |
| 2021-11-0417:17 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-21-056803 |
| 2021-10-2908:33 ET | 8-K | 8.01 Other events | 0001213900-21-055258 |
| 2021-09-0216:49 ET | SC 13D/A | Ownership report, active investor, amended | 0001213900-21-046415 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 15, 2026, 04:14 ET. Listed shows no prices and gives no investment advice.